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Abstract
Background: Excision repair cross-complementing group 1 (ERCC1) and group 2 (ERCC2), and X-ray repair
cross-complementing group 1 (XRCC1) proteins play important roles in the repair of DNA damage and adducts.
Single nucleotide polymorphisms (SNPs) of DNA repair genes are suspected to influence treatment effect and
survival of cancer patients. This study aimed to investigate the relationship between polymorphisms in ERCC2,
ERCC1 and XRCC1 genes and survival of non-smoking female patients with lung adenocarcinoma.
Methods: We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method
to evaluate SNPs in ERCC2, ERCC1 and XRCC1 genes among 257 patients.
Results: The overall median survival time (MST) was 13.07 months. Increasing numbers of either ERCC1 118 or
XRCC1 399 variant alleles were associated with shorter survival of non-smoking female lung adenocarcinoma
patients (Log-rank P < 0.001). The adjusted hazard ratios (HRs) for individuals with CT or TT genotype at ERCC1
Asn118Asn were 1.48 and 2.67 compared with those with CC genotype. For polymorphism of XRCC1 399, the
HRs were 1.28 and 2.68 for GA and AA genotype. When variant alleles across both polymorphisms were
combined to analysis, the increasing number of variant alleles was associated with decreasing overall survival.
Using the stepwise Cox regression analysis, we found that the polymorphisms in ERCC1 and XRCC1, tumor stage
and chemotherapy or radiotherapy status independently predicted overall survival of non-smoking female patients
with lung adenocarcinoma.
Conclusions: Genetic polymorphisms in ERCC1 and XRCC1 genes might be prognostic factors in non-smoking
female patients with lung adenocarcinoma.
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Background
Lung cancer is a major cause of cancer mortality world-
wide, and more than a million people in the world die
from the disease each year [1]. Adenocarcinoma accounts
for about 25% to 40% of all lung cancers, and is now the
most common form of lung cancer in women [2]. It is the
most frequent subtype occurring in those who have never
smoked. Five-year survival rate of lung cancer is at only
15% in the United States and even lower in China [3].
Genetic factors are considered to influence the treatment
effectiveness of lung cancer [4], and thus affect the prog-
nosis of patients. There are some molecular markers
showing potential as therapeutic and prognostic indica-
tors, but none could be used into clinical practice [5,6]. Of
these factors, DNA repair capacity (DRC) is an important
one. Several studies have shown associations between
inefficient DNA repair and lung cancer risk [7,8]. It is also
possible that individual DRC can affect the survival of
lung cancer patients. It has been speculated that single
nucleotide polymorphisms (SNPs) in DNA repair genes
may change gene expression and activity, hence influence
the effectiveness of cancer treatment and survival of
patients [9]. To test above possibility, we assess the rela-
tionship between survival of lung adenocarcinoma
patients and SNPs in three DNA repair genes, including
excision repair cross-complementing group 1 (ERCC1)
and group 2 (ERCC2), and X-ray repair cross-comple-
menting group 1 (XRCC1). ERCC2 is located in chromo-
some 19q13.2-13.3 and codes for an evolutionarily
conserved helicase, a subunit of TFIIH complex which is
essential for transcription and nucleotide excision repair
(NER). The common SNPs of ERCC2 gene is at codon 751
(A > C substitution at nucleotide position 35931, exon 23,
Lys>Gln, rs13181) and codon 312 (G >A substitution at
position 23951, exon 10, Asp>Asn, rs1799793). ERCC1 is
also located in chromosome 19q13.2-13.3 and codes for
a leading protein in NER, responsible for recognition of
DNA damage and removal of the damaged nucleotides.
The common SNP of ERCC1 gene is at codon 118 (C > T
substitution at exon 4, without amino acid change--Asn/
Asn, rs11615). The study showed that ERCC1 and ERCC2
mRNA levels were correlated with DRC [10]. XRCC1 pro-
tein plays a central role in base excision repair (BER) path-
way by interacting with other DNA repair proteins. The
most extensively studied SNP of XRCC1 gene is at codon
399 (G > A substitution at position 28152, exon 10,
Arg>Gln, rs25487), which has been reported to be associ-
ated with an altered DNA repair activity [11,12]. SNP ana-
lyzing involves little more than a blood sample and
relatively simple and precise polymerase chain reaction
(PCR)-based techniques, making it more practical in the
clinical testing than many other studied prognostic mark-
ers. Therefore, in this study we prospectively assess the
relationship between the four SNPs in DNA repair genes
and survival of non-smoking female patients with lung
adenocarcinoma.
Methods
Patient recruitment and follow-up
All patients were from the ongoing study of lung cancer in
non-smoking females, which started from July, 1999 in
Shenyang city, China. The human investigations were
approved by the Institutional Review Board of China
Medical University, and informed consent was obtained
from each participant or their representatives if direct con-
sent could not be obtained. All patients were unrelated
ethnic Han Chinese. Individual with a total of 100 ciga-
rettes in his lifetime was defined as a smoker, otherwise he
was considered as a non-smoker. Each participant
donated 10 ml venous blood and was interviewed to col-
lect demographic data and clinical information. For this
study, we identified 285 patients who were diagnosed
with histologically confirmed lung adenocarcinoma
(stage I-IV) between the years 1999 and 2004. The year
2004 was chosen as the last year of eligibility in order that
all participants have adequate follow-up. About the histo-
logical subtype of 285 patients, 228 were diagnosed using
surgical specimen and 57 using exfoliated cells of lung
adenocarcinoma patients whose tumor stages were deter-
mined by thoracic imageology.
Dates of death were obtained using at least one of the four
following methods: inpatient and outpatient medical
records, the registry of causes of death in Shenyang Center
for Disease Control and Prevention (CDC), registration
and presumption of death in Shenyang Public Security
Bureau, and telephone follow-up. Twenty eight patients
were lost to follow up. However, there was no significant
difference in the characteristics between the patients with
and without follow-up information. Finally, 257 patients
were included in this analysis.
DNA extraction and genotyping
Genomic DNA samples were extracted by guanidine
hydrochloride (GuHCl) method. SNP was analyzed by
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) method as described previ-
ously [13]. The PCR primers (Takara Biotechnology Dal-
ian Co. Ltd., China) for amplifying DNA fragment
containing the ERCC2 751, ERCC2 312, ERCC1 118 and
XRCC1 399 sites were 751 F5'-GCC CGC TCT GGA TTA
TAC G-3' and R5'-CTA TCA TCT CCT GGC CCC C-3', 312
F5'-CTG TTG GTG GGT GCC CGT ATC TGT TGG TCT-3'
and R5'-TAA TAT CGG GGC TCA CCC TGC AGC ACT
TCC T-3', 118 F5'-AGG ACC ACA GGA CAC GCA GA-3'
and R5'-CAT AGA ACA GTC CAG AAC AC-3', 399 F5'-TTG
TGC TTT CTC TGT GTC CA-3' and R5'-TCC TCC AGC CTT
TTC TGA TA-3', respectively. The PCR products wereBMC Cancer 2009, 9:439 http://www.biomedcentral.com/1471-2407/9/439
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digested with restriction enzyme (New England Biolabs,
Beverly, MA) PstI (for ERCC2 751), StyI (for ERCC2 312),
BsrdI (for ERCC1  118) and MspI (for XRCC1  399) to
determine the genotypes. A 10% masked and random
sample of patients was tested twice by different persons,
and the results were found to be concordant for all of the
masked duplicate sets.
Statistical analysis
The associations between overall survival and demo-
graphic characteristics, clinical features, and genetic SNPs
were estimated using the Kaplan-Meier method and Log-
rank test. Survival time was calculated from the date of
cancer diagnosis to the date of death or last follow-up. In
some analyses, we combined the heterozygous genotype
with the homozygous rare genotype as the particular
group in order to increase sample size. Univariate and
multivariable Cox proportional hazards regression mod-
els were performed to estimate crude hazard ratio (HR) or
adjusted HR and their 95% confidence intervals (CIs). The
stepwise Cox regression model was also used to determine
factors predictive of cancer prognosis, with a significant
level of P < 0.05 for entering and P > 0.10 for removal of
the variables. All the statistical analyses were performed
using Statistical Product and Service Solutions (SPSS)
v13.0.
Table 2: Genetic polymorphisms in DNA repair genes and survival of patients
Genotype Patients(%) MST(mon) Log-rank P HR(95%CI) Adjusted HR(95%CI)A
ERCC2 Lys751Gln
AA 194(75.5) 14.50 1.00 1.00
AC 59(23.0) 10.40 0.10 1.40(1.01-1.94) 1.32(0.95-1.84)
CC 4(1.5) 12.27 0.73(0.23-2.28) 0.79(0.25-2.48)
AC/CCB 63(24.5) 10.97 0.08 1.33(0.97-1.82) 1.27(0.92-1.75)
ERCC2 Asp312Asn
GG 229(89.1) 13.23 1.00 1.00
GA 27(10.5) 12.40 0.05 0.95(0.60-1.49) 0.95(0.60-1.49)
AA 1(0.4) 4.40 8.25(1.12-60.60) 8.55(1.14-64.25)
GA/AAC 28(10.9) 9.83 0.96 0.99(0.63-1.54) 0.99(0.63-1.54)
ERCC1 Asn118Asn
CC 140(54.5) 17.23 1.00 1.00
CT 94(36.6) 11.07 < 0.001 1.58(1.18-2.12) 1.48(1.10-1.99)
TT 23(8.9) 6.20 2.82(1.72-4.62) 2.67(1.62-4.40)
XRCC1 Arg399Gln
GG 117(45.5) 19.10 1.00 1.00
GA 102(39.7) 10.40 < 0.001 1.41(1.05-1.91) 1.28(0.95-1.74)
AA 38(14.8) 9.23 2.33(1.56-3.47) 2.68(1.79-4.02)
Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
AHR adjusted for age, stage, surgical operation and chemotherapy or radiotherapy.
BLog-rank P and HR were calculated compared with wild genotype(AA) of ERCC2 751 polymorphism.
CLog-rank P and HR were calculated compared with wild genotype(GG) of ERCC2 312 polymorphism.
Table 1: Patient characteristics and clinical features
Variable Patients (%) MST(mon) Log-rank P value HR (95%CI)
Age (years)
≤50 105(40.9) 14.93 0.493 1.00
>50 152(59.1) 12.47 1.10(0.84-1.45)
Tumor stage
I 44(17.1) 45.80 1.00
II 34(13.2) 18.57 < 0.001 2.48(1.36-4.53)
III 149(58.0) 11.07 3.46(2.14-5.61)
IV 30(11.7) 9.07 4.66(2.59-8.37)
Surgical operation
No 53(20.6) 6.20 0.005 1.00
Yes 204(79.4) 15.50 0.61(0.44-0.86)
Chemotherapy or radiotherapy
No 31(12.1) 9.00 0.803 1.00
Yes 226(87.9) 13.30 0.94(0.59-1.51)
Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.BMC Cancer 2009, 9:439 http://www.biomedcentral.com/1471-2407/9/439
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Results
Patient characteristics
The mean age of patients was 51.16 ± 9.48 years (range
18-75 years). The distribution of characteristics and clini-
cal features of 257 lung adenocarcinoma patients were
shown in Table 1. There were 206 deaths. The overall
median survival time (MST) was 13.07 months. As Table
1 showed, patients with advanced cancer or without sur-
gical operation had significantly shorter MSTs (Log-rank P
< 0.05). Univariate Cox regression analysis suggested that
the risks of death of lung adenocarcinoma were increased
in patients with stage II, III and IV compared with those
with stage I (HRs were 2.48, 3.46 and 4.66, respectively).
The result also showed that the patients undergoing surgi-
cal operation had a decreased risk of death (HR = 0.61).
Genotype frequencies of genetic polymorphisms
Table 2 showed the genotype frequencies of four SNPs in
257 patients. All genotype frequencies of these four poly-
morphisms were found to be in Hardy-Weinberg equilib-
rium. The variant allele frequencies were 13.0% for
ERCC2 751, 5.6% for ERCC2 312, 27.2% for ERCC1 118
and 34.6% for XRCC1 399 polymorphism. No associa-
tions were found between genotypes and age, tumor stage,
surgical operation, chemotherapy or radiotherapy (data
not shown).
Genetic polymorphisms and survival of patients
The associations between genotypes of four SNPs and sur-
vival of non-smoking female patients with lung adenocar-
cinoma were suggested in Table 2. Patients with CT or TT
genotype at ERCC1  Asn118Asn showed significantly
shorter survival time than those with CC genotype (11.07,
6.20 months versus 17.23 months) (Log-rank test, P <
0.001). In terms of XRCC1 399 polymorphism, the differ-
ence in the MSTs among patients with GG (19.10
months), GA (10.40 months) and AA (9.23 months) was
statistically significant (Log-rank test, P < 0.001). However
no associations were found between two SNPs of ERCC2
gene and the overall survival of patients.
In the further analysis, lung adenocarcinoma patients
were stratified by stage. There were no significant differ-
ences in survival times of stage I-II patients with variant
genotypes of four SNPs. For patients with stage III or IV,
Kaplan-Meier analyses proved that individuals with heter-
ozygous variant or homozygous variant genotype at
ERCC1  Asn118Asn or XRCC1  Arg399Gln had shorter
MSTs than those with wild genotype (Figure 1). The MSTs
of patients with CC, CT and TT genotype at ERCC1
Asn118Asn were 14.53, 9.57 and 5.03 months and the
difference was significant (Log-rank P < 0.001). For
XRCC1 399 polymorphism, patients with GA or AA geno-
type lived shorter than those with GG genotype and corre-
sponding MSTs were 9.57, 4.27 and 14.20 months(Log-
rank P < 0.001). There were no differences in MSTs
according to genotypes of ERCC2 751 or 312 polymor-
phism.
In the Cox regression model, after adjusting for age, tumor
stage, surgical operation and chemotherapy or radiother-
apy, variant genotypes of ERCC1 118 or XRCC1 399 pol-
ymorphism were associated with higher risks of death for
non-smoking female patients with lung adenocarcinoma
(Table 2). With the CC genotype at ERCC1 Asn118Asn
being the reference, the HR for CT genotype was 1.48 (P =
0.009) compared to 2.67 (P < 0.001) in the TT genotype.
In terms of XRCC1 399 polymorphism, we found that
compared with those carrying GG genotype, the HRs were
1.28 (P = 0.109) and 2.68 (P < 0.001) for individuals with
GA and AA genotype, respectively.
In addition to evaluating the genetic polymorphisms sep-
arately, we studied the association between patients' sur-
vival and the total number of variant alleles of ERCC1 and
Kaplan-Meier curves for patients with stage III-IV by (A)  ERCC1 118 genotypes and (B) XRCC1 399 genotypes Figure 1
Kaplan-Meier curves for patients with stage III-IV by 
(A) ERCC1 118 genotypes and (B) XRCC1 399 geno-
types.
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XRCC1  polymorphisms (Table 3). In the double
homozygous group (0 variant allele), the overall MST was
25.10 months. As the number of variant alleles increased,
the MSTs decreased to 13.07, 9.27, 6.30 and 3.87 months.
The Log-rank test was statistically significant (P < 0.001).
The HRs for individuals with 1, 2, 3, 4 variant allele(s)
were 1.52, 2.33, 2.98 and 9.24 compared with those car-
rying 0 variant allele. Besides, the effect was also conspic-
uous for the patients with stage III-IV (Log-rank P < 0.001)
but not significant for those with stage I-II (P = 0.145).
Furthermore we evaluated an interaction effect of the two
SNPs on the survival of non-smoking female patients with
lung adenocarcinoma. We found that individuals carrying
both ERCC1 118 and XRCC1 399 variant alleles were at a
higher death risk of lung adenocarcinoma than those with
only one of them (adjusted HRs were 2.44, 1.79 and 1.64,
respectively) (Table 4).
Stepwise Cox proportional hazard analysis was used to
study the relationship between factors including demo-
graphic characteristics, clinical features and genetic SNPs
and survival of non-smoking female patients with lung
adenocarcinoma. Four variables (stage, chemotherapy or
radiotherapy,  ERCC1  118 and XRCC1  399 polymor-
phisms) were included in the Cox regression model
(Table 5).
Discussion
In this study, we explored the relationship between SNPs
of three DNA repair genes and survival of non-smoking
female patients with lung adenocarcinoma in China. In
WHO Western Pacific Region, lung cancer was the com-
monest cancer cause of death in women and the propor-
tion of adenocarcinoma in lung cancer has increased
quickly in both genders over the last few decades [14]. So
we focused our study on lung adenocarcinoma in females
who were requested to be non-smokers in order to control
the confounding influence of smoking. This study showed
that being advanced stage, without chemotherapy or radi-
otherapy, carrying variant genotypes at ERCC1
Asn118Asn or XRCC1 Arg399Gln were proved to be unfa-
vorable prognostic factors for lung adenocarcinoma in
Chinese non-smoking women. However, the associations
have not been found between ERCC2 751 or 312 poly-
morphism and survival of lung adenocarcinoma.
The XRCC1 protein is considered to play an important
role in both base excision repair and single-strand break
repair. XRCC1 Arg399Gln polymorphism was the com-
monest one among more than 60 validated SNPs in
XRCC1 gene and showed no major variations by ethnicity
[15]. This polymorphism has been suggested to be a risk
Table 4: Interaction of ERCC1 and XRCC1 polymorphisms on 
survival of lung adenocarcinoma
ERCC1 CC ERCC1 CT/TT
XRCC1 MST HR(95%CI)A MST HR(95%CI)A
GG 25.10 1.00 13.30 1.79(1.16-2.76)
GA/AA 12.47 1.64(1.11-2.44) 8.60 2.44(1.63-3.65)
Abbreviation: MST, median survival time; HR, hazard ratio; CI, 
confidence interval.
AHR and 95%CI were calculated by Cox regression, with the ERCC1 
wild genotype (CC) and XRCC1 wild genotype (GG) as the reference 
group;HRs were adjusted for age, stage, surgical operation and 
chemotherapy or radiotherapy.
Table 3: Genetic polymorphisms in combination of ERCC1 and XRCC1 and survival of patients
Stage Combined genotype Patients(%) MST(mon) Log-rank P HR(95%CI)a
all 0 variant 67(26.1) 25.10 1.00
1 variant allele 100(38.9) 13.07 1.52(1.04-2.22)
2 variant alleles 58(22.6) 9.27 < 0.001 2.33(1.54-3.50)
3 variant alleles 26(10.1) 6.30 2.98(1.76-5.04)
4 variant alleles 6(2.3) 3.87 9.24(3.50-24.44)
I and II 0 variant 26(33.3) 45.80 1.00
1 variant allele 30(38.5) 22.27 1.98(0.86-4.58)
2 variant alleles 14(17.9) 11.60 0.145 2.81(1.10-7.13)
3 variant alleles 6(7.7) --b 1.41(0.26-6.75)
4 variant alleles 2 (2.6) 17.27 9.05(1.04-78.76)
III and IV 0 variant 41(22.9) 19.10 1.00
1 variant allele 70(39.1) 11.17 1.54(0.98-2.39)
2 variant alleles 44(24.6) 8.93 < 0.001 2.29(1.44-3.66)
3 variant alleles 20(11.2) 5.83 3.69(2.06-6.62)
4 variant alleles 4(2.2) 3.63 18.50(5.68-60.23)
Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
aHR adjusted for age, stage, surgical operation and chemotherapy or radiotherapy.
bMST for this genotype could not be calculated.BMC Cancer 2009, 9:439 http://www.biomedcentral.com/1471-2407/9/439
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factor for the development of lung cancer [16-20]. In our
previous study, a significant association between XRCC1
399Gln/Gln genotype and risk of lung cancer in Chinese
non-smoking women was found [21]. In the present
study, we found that non-smoking female lung adenocar-
cinoma patients with AA genotype at XRCC1 Arg399Gln
had a shorter survival time (9.23 months vs. 19.10
months) and higher risk of death (adjusted HR = 2.68,
95%CI = 1.79-4.02) than those with GG genotype. It is
consistent with other studies, although those results were
obtained from the subjects of all genders, smoking status
and histopathologic subtypes [22-24].
As for ERCC1  Asn118Asn polymorphism, we observed
that the patients with CT or TT genotype showed a signif-
icantly shorter survival time than those with CC genotype
(11.07 and 6.20 versus 17.23 months). In the multivaria-
ble Cox regression, ERCC1 118 variant genotype (CT/TT)
remained prognostic factors of lung adenocarcinoma (HR
= 1.60, P value = 0.001). To date, only a few studies have
examined the relationship between ERCC1  polymor-
phism and survival of lung cancer, and they didn't control
the influence of gender, smoking status and histopatho-
logic subtypes [25-27]. In terms of chemotherapy
response, a few studies suggested an association between
ERCC1 Asn118Asn polymorphism and response to plati-
num-based treatment of lung cancer [25,27,28]. Although
these studies have shown possible relationship between
ERCC1 polymorphism and effectiveness of cancer treat-
ment or survival of cancer patients, the biological effect of
this synonymous SNP is unclear.
In our study, no associations were found between the
overall survival and two SNPs of ERCC2 gene. This is con-
sistent with other studies [22,25,29], but there are studies
showing an opposite effect [24]. The explanation for these
discordant results remains to be elucidated.
Many clinical features may play important roles in the sur-
vival of cancer patients. The multivariable Cox regression
in this study showed that being advanced stage (III+IV)
and without chemotherapy or radiotherapy treatment
were independent unfavorable prognostic factor for lung
adenocarcinoma in non-smoking female population. Sur-
gical status wasn't included in the stepwise Cox model
maybe because the surgical treatment is decided by the
patients' conditions such as tumor stage and histopatho-
logic subtypes, so the surgical status may be a dependent
variable but not an independent prognostic factor.
Genetic polymorphisms as either prognostic or predictive
biomarkers have many advantages, especially in the
advanced cancer setting. First of all, the biological speci-
men for detecting SNP is easily to obtain. Second, the
detecting method is simple, precise and practical. Finally,
in the advanced cancer setting, diagnoses are made using
specialized and mostly body-harmed method; otherwise
SNP detecting can avoid these problems.
In conclusion, this study analyzed four SNPs in three DNA
repair genes in relation to survival of non-smoking female
patients with lung adenocarcinoma in China. The results
suggested that besides clinical features such as tumor stage
and chemotherapy or radiotherapy treatment, polymor-
phisms of ERCC1  Asn118Asn and XRCC1  Arg399Gln
were associated with survival of patients. Because DNA
repair is a complex system including many pathways and
genes, larger studies with more genetic polymorphisms,
even haplotypes, in different ethnic populations and the
functional or biological relevance of these polymor-
phisms are needed to confirm our conclusions.
Conclusions
Genetic polymorphisms in ERCC1  and  XRCC1  genes
might be prognostic factors in non-smoking female
patients with lung adenocarcinoma.
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